Stock EQL EQL PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages EQL Pharma AB

Equities

EQL

SE0005497732

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 23:00:00 01/05/2024 BST 		5-day change 1st Jan Change
44.2 SEK +1.84% Intraday chart for EQL Pharma AB +2.79% +32.34%
04-22 EQL Pharma AB Announces Mellozzan Launched in Germany and Austria CI
02-13 EQL Pharma AB Provides Sales Guidance for the Year 2023/24 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EQL Pharma AB Announces Mellozzan Launched in Germany and Austria
EQL Pharma AB Provides Sales Guidance for the Year 2023/24
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
EQL Pharma AB Announces its Mellozzan Gains Marketing Approval by Health Authorities in Germany and Austria
EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2023
EQL Pharma AB Launches in Denmark and Norway by License Partner Medice Arzneimittel Pütter Gmbh & Co. Kg
EQL Pharma Out-Licenses Methenamine Hippurate to Dr. Pfleger Arzneimittel for the German Market
EQL Pharma Enters into a Strategic Licensing Agreement with Adalvo for Mellozzan Outside of Europe
EQL Pharma Out-Licenses Methenamine Hippurate to Laboratoires Majorelle for the French Market
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.
EQL Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
EQL Pharma AB Signs License Agreement with A Pharmaceutical Company in Turkiye for Mellozzan
EQL Pharma Recruits Carl Lindgren as Chief Business Development Officer
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
EQL Pharma Enters into Exclusive Out-Licensing Agreement for EQL's Proprietary Product Mellozzan
EQL Pharma AB Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One Step
EQL Pharma AB Announces Executive Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EQL Stock
  4. News EQL Pharma AB
  5. Other languages